Can NVO Maintain Obesity Leadership With Next-Generation Candidates?

Novo Nordisk (NVO) has revised down its 2025 sales and profit outlook, citing slower uptake of Wegovy and Ozempic amidst intensifying competition from Eli Lilly (LLY) and compounded alternatives in the U.S. obesity market. To counter this, NVO is strategically bolstering its pipeline with next-generation obesity candidates, including CagriSema which is slated for regulatory filing in 2026 despite lower-than-expected weight loss, and the promising early-stage amycretin. Additionally, the company is pursuing acquisitions and licensing deals, such as a $2.2 billion agreement with Septerna, to solidify its long-term leadership in the highly competitive obesity space despite near-term growth pressures.

Analysis

Novo Nordisk (NVO) is facing significant near-term headwinds, evidenced by its downward revision of the 2025 sales and profit outlook. This revision is attributed to slower-than-expected uptake for its blockbuster semaglutide products, Wegovy and Ozempic, a direct result of intensifying competition from Eli Lilly's (LLY) rapidly adopted tirzepatide drugs, Mounjaro and Zepbound, and the availability of compounded alternatives in the U.S. market. In response, NVO is executing a multi-pronged defensive strategy centered on its pipeline. While its most advanced next-generation candidate, CagriSema, met primary endpoints in late-stage studies, it demonstrated a lower-than-expected level of weight loss, with a regulatory submission not planned until 2026. This places greater importance on other pipeline assets, such as the promising early-stage candidate amycretin—which outperformed Wegovy in a Phase I study—and cagrilintide as a monotherapy. NVO is further bolstering its long-term position through strategic capital allocation, including the 2023 acquisition of Inversago Pharmaceuticals and a recent $2.2 billion licensing deal with Septerna, signaling a clear focus on sustaining its leadership in the obesity market beyond its current product cycle.

Key Decisions for Investors

• Investors should recognize that the NVO investment thesis is shifting from near-term commercial dominance to long-term pipeline execution, and should closely monitor the sales trajectory of Wegovy against Eli Lilly’s Zepbound to gauge the full impact of the competitive pressures cited in the revised 2025 guidance.
• Pay close attention to upcoming clinical data from NVO's earlier-stage candidates, particularly amycretin, as the reported 'lower-than-expected' efficacy for the late-stage CagriSema increases the burden on these assets to deliver superior results to defend market leadership post-2026.
• Given Eli Lilly's demonstrated commercial momentum and its own robust pipeline, including an oral obesity pill targeting a 2025 filing, a relative value assessment between NVO and LLY is critical, as LLY appears positioned to continue gaining market share in the near term.
• The significant stock decline in Viking Therapeutics (VKTX) following mixed mid-stage trial results for its oral obesity candidate serves as a salient reminder of the high binary risk associated with development-stage competitors in this space.